Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer
2015 ASCO Annual MeetingChristopher Sweeney, MBBS, of Dana-Farber Cancer Institute discusses the EnzaMet and EnzaRad study designs, eligibility requirements, and endpoints (Abstracts TPS5077 and TPS5078).
Related Videos
Asher Chanan-Khan, MD, Summarizes Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL
Asher Alban Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discusses an important treatment option that significantly improved overall response rate and reduced risk of progres...
Lee S. Schwartzberg, MD, on ICLIO: Adopting Immunotherapy in the Community Setting
Lee S. Schwartzberg, MD, of The West Clinic, describes a new initiative of the Association of Community Cancer Centers, designed to speed the adoption of immunotherapeutics in the ...
Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden
James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patien...
Claus Garbe, MD, Summarizes Results of the DECOG Trial on SLNB-Positive Melanoma
Claus Garbe, MD, of the University of Tuebingen, discusses the survival of sentinel lymph node biopsy–positive melanoma patients with and without complete lymph node dissection (
Claus Garbe, MD, and Anthony J. Olszanski, RPh, MD, on The DECOG Trial on Sentinel Lymph Node–Positive Melanoma
Claus Garbe, MD, of the University of Tuebingen, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss the survival of sentinel lymph node-positiv...
